Anavex Life Sciences Corp (AVXL)

[falconer66a]

Blarcamesine Prophylaxis Won't Be "Proven" But Discovered

They won't be able to prove that...[blarcamesine or other Anavex sigma-1 receptor agonists will have profound prophylactic powers].

That's right. The disease-preventing powers of the Anavex molecules will not be proven but, rather, discovered.

When hundreds of thousands of people are taking blarcamesine to treat their Alzheimer's or Parkinson's diseases it will be noted, discovered, by both lay people (caregivers and patients themselves) and by medical personnel that when taking blarcamesine patients simply sleep better and have far fewer diseases. It will become clear that the taking of blarcamesine markedly reduces the symptoms or onset of a wide range of geriatric, age-related diseases and conditions.

From private, yet-undisclosed studies on a number of organisms used in aging studies Anavex already knows this. But the evidence for blarcamesine's prophylactic powers won't be released until the drug has been approved for a CNS disease and is being taken by thousands. When that happens, the release of Anavex's studies on blarcamesine's disease prophylaxis will prompt confirmatory (or disqualifying) studies of people on blarcamesine to see if disease prophylaxis actually has occurred with those taking the drug. The compiled data on the matter will decide the issue; favorably.